A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 383 participants.

Also called NCT05048719

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 383 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05048719
  • EudraCT 2021-002806-29
Other papers using this trial's data
  • Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study Lancet (London, England), 2023-08-05 DOI, PubMed 37369232 PubMed links an erratum for this paper. Erratum: PMID 37659778; Erratum: PMID 38944526

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Hungary, Poland, Puerto Rico, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05048719. Randomized; double masking; primary purpose treatment. Start 2021-09-15 (actual); primary completion 2022-09-30 (actual). Results posted on 2023-10-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Intervention (Drug)
LY3502970
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05048719
Content hash
663b3cd2b1eae67955bcdf4d7a8fa94b11becbb94863147ea90b10283fd9b3e6